Long Term Follow up Study on a Large Group of Patients with Congenital Factor XIII Deficiency Treated Prophylactically with Fibrogammin P®
| Author | Majid Naderi | en |
| Author | Mehran Karimi | en |
| Author | Maryam Sadat Hosseini | en |
| Author | Es′hagh Moradi | en |
| Author | Morteza Shamsizadeh | en |
| Author | Akbar Dorgalaleh | en |
| Issued Date | 2016-04-30 | en |
| Abstract | Factor XIII deficiency (FXIIID) is an extremely rare hemorrhagic disorder with a prevalence of 1/3-5 million. Management of disease is performed by fresh frozen plasma (FFP), Cryoprecipitate (CP) or FXIII concentrate (Fibrogammin P®). Our objective was to assess safety and effectiveness of Fibrogammin P® in patients with FXIIID. For this purpose we designed this long-term follow up study on a large group of patients with FXIIID. | en |
| DOI | https://doi.org/10.22037/ijpr.2016.1841 | en |
| Keyword | Factor XIII deficiency | en |
| Keyword | Fibrogammin P® | en |
| Keyword | Safety | en |
| Keyword | Effectiveness | en |
| Publisher | Brieflands | en |
| Title | Long Term Follow up Study on a Large Group of Patients with Congenital Factor XIII Deficiency Treated Prophylactically with Fibrogammin P® | en |
| Type | Original Article | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- ijpr-15-635.pdf
- Size:
- 540.42 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF